Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease

Doyeon Hwang, Kyung Woo Park, Joo Myung Lee, Tae Min Rhee, Myeong Ki Hong, Yangsoo Jang, Marco Valgimigli, Antonio Colombo, Martine Gilard, Tullio Palmerini, Gregg W. Stone, Hyo Soo Kim

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background We compared efficacy and safety of short- (3 or 6 months) versus long-term (≥12 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation, according to the presence of chronic kidney disease (CKD). Methods Patient-level pooled analysis was performed with 7242 patients (87.2% with 2nd generation DES) from 5 randomized controlled trials. Results In both CKD (1273 patients) and non-CKD (5969 patients) population, the rates of patient-oriented composite outcomes at 1-year (POCO, all-cause death, any myocardial infarction [MI], stroke and TIMI major bleeding) were not different between the short- and long-term DAPT (hazard ratio [HR] 1.19, 95% confidence interval [CI] 0.76–1.86, P =.449 in CKD population; HR 1.14, 95% CI 0.83–1.56, P =.434 in non-CKD population). The rates of coronary thrombotic events (any MI and definite/probable stent thrombosis) also did not differ between short- and long-term DAPT in either CKD or non-CKD population. As for bleeding events, long-term DAPT increased the TIMI major bleeding (HR 2.91, 95% CI 1.31–6.48, P =.009) in non-CKD population. The similar trend was observed with long-term DAPT in CKD population. But it did not reach statistical significance (HR 3.15, 95% CI 0.64–15.63, P =.160). Conclusions The rates of POCO and coronary thrombotic events were significantly higher in patients with CKD compared with those without CKD, which were not affected by short- or long-term DAPT. Higher bleeding incidence by long-term DAPT was only observed in non-CKD patients but not in CKD patients. Further large scale studies are warranted to confirm our findings.

Original languageEnglish
Pages (from-to)103-112
Number of pages10
JournalAmerican heart journal
Publication statusPublished - 2018 Mar

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this